triple negative breast cancer Clinical Research Trials

Please select a valid location from the dropdown

Found 570 clinical trials

featured

A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

cancer

advanced cancer

128 views
14 Dec, 2020
4 locations

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

patients with triple-negative breast cancer. Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who need adjuvant chemotherapy after breast surgery as well as

invasive carcinoma

doxorubicin

invasive breast cancer

primary tumor

paclitaxel

82 views
08 Nov, 2020
10 locations

Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer

endocrine therapy for operable ER-beta positive, ER-alpha/PR negative, Her-2 negative breast cancer(triple negative breast cancer, TNBC) patients. The ER-beta positive TNBC patients who had undergone

hormone therapy

mastectomy

estrogen receptor

breast-conserving surgery

endocrine therapy

7 views
08 Nov, 2020

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

(EC-TCb) in triple-negative breast cancer.

epirubicin

paclitaxel

cyclophosphamide

carcinoma

docetaxel

90 views
16 Apr, 2020
27 locations

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

docetaxel (EC4-T4) verses 6 cycles of weekly paclitaxel combined with carboplatin (PCb*6) in the adjuvant chemotherapy of non-triple negative breast cancer patients. The study is divided in to 2

epidermal growth factor receptor

invasive breast cancer

cish

paclitaxel

trastuzumab

2 views
15 Mar, 2020
1 location

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer

This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

invasive breast cancer

paclitaxel

EGFR

triple negative breast cancer

adjuvant therapy

10 views
08 Nov, 2020
1 location

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15% of all cases diagnosed correspond to the triple negative subtype. Triple negative breast cancer

2 views
22 Jul, 2019
1 location

Vaccination of Triple Negative Breast Cancer Patients

The purpose of this research is to compare the effect on breast cancer of using a new experimental breast cancer vaccine (used to stimulate immune cell production) with chemotherapy and surgery versus the usual treatment of chemotherapy and surgery.

cancer

breast cancer

triple negative breast cancer